Physician profile
Robert Ortiz
NPI 1154679694
$4,918.97
in general payments reported to CMS, 2019-2025
24 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $357 · 2021: $562 · 2022: $389 · 2023: $412 · 2024: $1,048 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,716 · Entertainment: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.39 |
| Entertainment | $122.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $725.88 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $617.50 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $502.20 | 2021-2025 | Tecnis Iol, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $412.38 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $351.45 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $290.48 | 2019-2021 | |
| New World Medical,INC. | $240.64 | 2024-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Aerie Pharmaceuticals, INC. | $221.32 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $206.58 | 2023-2025 | Toric, Stellaris, Vyzulta |
| Coopervision INC. | $205.82 | 2023-2025 | Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $182.92 | 2019-2025 | Tryptyr, Hydrus Microstent |
| Dompe US, INC. | $179.19 | 2022-2025 | Oxervate |
| Harrow Eye, LLC | $160.23 | 2025 | Vevye |
| Allergan, INC. | $143.05 | 2020-2022 | |
| Optos, INC. | $122.97 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $60.94 | 2024-2025 | Izervay |
| Sight Sciences, INC. | $50.56 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $49.93 | 2024 | Cirrus Hd-Oct |
| Oyster Point Pharma, INC. | $44.06 | 2023-2025 | Tyrvaya |
| Ivantis, INC | $43.67 | 2021 | |
| Mallinckrodt Hospital Products INC. | $38.54 | 2021-2025 | Acthar |
| Johnson & Johnson Vision Care, INC. | $35.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.68 | 2022 | |
| Alcon Research LLC | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.